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Summary
Polymorbid patients, diverse diagnostic and therapeutic op-
tions, more complex hospital structures, financial incent-
ives, benchmarking, as well as perceptional and societal
changes put pressure on medical doctors, specifically if
medical errors surface. This is particularly true for the
emergency department setting, where patients face delayed
or erroneous initial diagnostic or therapeutic measures and
costly hospital stays due to sub-optimal triage.
A “biomarker” is any laboratory tool with the potential bet-
ter to detect and characterise diseases, to simplify com-
plex clinical algorithms and to improve clinical problem
solving in routine care. They must be embedded in clinical
algorithms to complement and not replace basic medical
skills. Unselected ordering of laboratory tests and short-
comings in test performance and interpretation contribute
to diagnostic errors. Test results may be ambiguous with
false positive or false negative results and generate unne-
cessary harm and costs. Laboratory tests should only be
ordered, if results have clinical consequences. In studies,
we must move beyond the observational reporting and
meta-analysing of diagnostic accuracies for biomarkers. In-
stead, specific cut-off ranges should be proposed and inter-
vention studies conducted to prove outcome relevant im-
pacts on patient care.
The focus of this review is to exemplify the appropriate
use of selected laboratory tests in the emergency setting
for which randomised-controlled intervention studies have
proven clinical benefit. Herein, we focus on initial patient
triage and allocation of treatment opportunities in patients
with cardiorespiratory diseases in the emergency depart-
ment. The following five biomarkers will be discussed:
proadrenomedullin for prognostic triage assessment and
site-of-care decisions, cardiac troponin for acute myocardi-
al infarction, natriuretic peptides for acute heart failure, D-
dimers for venous thromboembolism, C-reactive protein as
a marker of inflammation, and procalcitonin for antibiotic
stewardship in infections of the respiratory tract and sepsis.
For these markers we provide an overview on physiopatho-
logy, historical evolution of evidence, strengths and limita-
tions for a rational implementation into clinical algorithms.
We critically discuss results from key intervention trials
that led to their use in clinical routine and potential future
indications.
The rational for the use of all these biomarkers, is to tackle,
first, diagnostic ambiguity and consecutive defensive
medicine, second, delayed and sub-optimal therapeutic de-
cisions, and third, prognostic uncertainty with misguided
triage and site-of-care decisions all contributing to the
waste of our limited health care resources. A multifaceted
approach for a more targeted management of medical pa-
tients from emergency admission to discharge including
biomarkers, will translate into better resource use, shorter
length of hospital stay, reduced overall costs, improved pa-
tients satisfaction and outcomes in terms of mortality and
re-hospitalisation. Hopefully, the concepts outlined in this
review will help the reader to improve their diagnostic
skills and become more parsimonious laboratory test re-
questers.
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The ever changing medical setting – a
small history of time
In the seventies, quality of medical care was considered
to be good. Life-expectancy, for example in Switzerland,
was around 70 years, less than 3% of the population was
more than 80 years old. Average length of hospital stay was
around three weeks, fee-for-service was the reimbursement
system of choice and healthcare costs consumed around
5% of the gross national domestic product [1].
A minority of patients were admitted through the emer-
gency department (ED) [2]. Community-acquired pneu-
monia (CAP) worldwide was susceptible to narrow-spec-
trum antibiotics and generally treated for two weeks or
more, allegedly to avoid recurrence and antimicrobial res-
istance. Clinically suspected acute myocardial infarction
(AMI) was confirmed electrocardiographically and by el-
evated circulating creatine kinase levels, and treated with
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bed rest, oxygen, rhythm monitoring, sedatives and
opioids. “Cancer” was typically considered to be a final
diagnosis and pulmonary embolism was frequently dia-
gnosed at autopsy only.
A large fraction of clinical knowledge for internists could
be comprehensively summarised in a one volume textbook,
such as Harrison’s Principles of Internal Medicine. A doc-
tor’s ruling was considered to be “state of the art”, and legal
aspects and malpractice insurance fees were negligible [3].
In 2015, quality of medical care is considered to be good.
In Switzerland, life-expectancy is almost 85 years and
among the highest in the world, with a doubling of the
population older than 80 years as compared with four dec-
ades ago. Average length of hospital stay is around seven
days, a case-based reimbursement system by diagnosis-re-
lated groups (DRGs) has been implemented and healthcare
costs consume around 12% of the gross national domestic
product [1].
EDs provide 75% or more of medical admissions of usually
multimorbid patients with polypharmacy. “Door-to-
needle” time has become a dominant benchmark to max-
imise outcome in an interdisciplinary setting that involves
highly-skilled nurses, generalists and specialist physicians.
Microbiological cultures are routinely plated to detect mul-
tiresistant organisms in patients hospitalised with CAP,
who are treated with steroids [269] and antibiotics for a
mean of less than 6 days and fewer complications, if pro-
calcitonin (PCT)-guided [4, 5]. For chest pain, standard
protocols demand the use of high-sensitivity cardiac tro-
ponin rapidly to rule-out or rule-in AMI for early revas-
cularisation and monitoring in costly coronary or intensive
care units [6, 7]. Clinical probability assessment and meas-
urement of D-dimer in low- and moderate-risk patients
should ensure that suspected pulmonary embolism can be
safely ruled out, without the need for additional imaging
[8, 9]. “Cancer” is not accepted anymore as a “final” dia-
gnosis. Molecular subtyping on a cellular level, detailed
radiographic staging and customised oncological therapy
with monoclonal antibodies are routinely performed. This
yields, overall, a superior cure and survival rate for “malig-
nant” tumours as compared with diseases previously con-
sidered to be more “benign”, such as congestive heart fail-
ure (CHF).
Today, as you read this review in PDF format online, it is –
at least in part – updated by more timely and widely access-
ible information on the internet. Expectations of society re-
garding healthcare have markedly increased. Patient safety
drives international efforts to measure and publish the rate
of errors and error-related harm. [3] One-third of patients
recall a diagnostic error that affected themselves, a family
member, or close friend [10] and 55% of surveyed patients
listed a diagnostic error as their chief concern when seeing
a physician [11]. Malpractice claims against US internists
are most frequently due to errors in diagnosis and conse-
quent suboptimal therapy and patient outcome [12].
Apparently, today we perceive a more urgent need for a
safe and efficient, but even more personalised, approach
of routine medical and nursing care to patients with com-
mon complaints. With this aim, laboratory tests can be of
help if the indication for ordering is not excessive and un-
selected but is based on rational criteria. Their performance
should be validated in randomised controlled trials in set-
tings appropriate for routine care. The often misinterpreted
term “biomarkers” refers to their role as specific mark-
ers of biological processes in a given disease state. This is
the rational foundation for the belief that they have high
potential to individualise clinical care with improved risk
stratification, site-of-care decisions, diagnosis and treat-
ment selection. This is not only for selected individuals
with neoplastic cases but for common diseases in an every-
day patient, therefore providing routine personalised emer-
gency care for all.
Personalised emergency medicine –
from clinically selected individuals to
risk-adapted standard of care
The term “personalised medicine” suggests an approach to
care that is based on individuals rather than groups. This is
not a new concept per se. Since ancient times, caregivers
considered individual characteristics such as age, co-exist-
ing conditions, preferences, and beliefs in crafting an per-
sonal management strategy. The term personalised medi-
cine became fashionable again with the recent use of in-
dividual genomic information in prescribing an expensive
and side-effect prone therapy, such as customised mono-
clonal antibodies in oncology or abacvir for HIV treat-
ment. Thereby, the genetic signature of a patient predicts
treatment success or failure or allergic complications and
has thus cost-considerations. Testing for human epidermal
growth factor receptor type 2 (HER2) helps selection of
breast cancer patients who will benefit from trastuzumab
[13]. Testing for the KRAS mutation helps selection of
patients most likely benefiting from therapies inhibiting
the epidermal growth factor receptor [14]. Sequencing of
whole genome, the epigenome, transcripts, microRNA, re-
spectively, proteomics or metabolomics have the potential
for further improved diagnostics, prognostic assessment,
therapeutic targets and stratified treatments for cancer and
rare disorders. However, these tools are costly and time-
consuming and, therefore, not readily available as point-of-
care test for early risk stratification in the emergency set-
ting. In addition, to date individual genomic variants have
variable penetrance and minor impact in common illnesses,
such as cardiorespiratory diseases. For example, currently
available genetic tests add no additional clinical useful in-
formation in guiding anticoagulation [15] or cardiovascu-
lar risk profiling. For these reasons, the vast majority of
acutely ill patients, such as the masses treated in the ED, do
Figure 1
Combined clinical and biomarker assessment for a personalised
emergency triage, therapeutic intervention and site of care
decisions.
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currently not benefit from stratification by tests on the ge-
netic or molecular level.
In contrast, blood circulating biomarkers play an important
role in the current diagnostic work-up of ED patients. A
biomarker may be defined as any protein or other macro-
molecule that can be objectively measured and evaluated
as an indicator of normal biological processes, pathological
processes, course of diseases or pharmacological responses
to a therapeutic intervention. Readily measurable biomark-
ers provide important information about aetiology of a dis-
ease, and the need for interventions and prognosis. Dia-
gnostic biomarkers confirm the presence or absence of a
disease. Thereby, biomarker results need to be interpreted
in the context of the pre-test probability and cut-off ranges
are to be preferred to dichotomous and overly simplistic
cut-offs. A high specificity and a high positive predictive
value is required to “rule in” a disease (e.g. a PCT level
of 0.5 ng/ml to prescribe antibiotic therapy in respiratory
tract infections). Conversely, a high sensitivity and a high
negative predictive value is needed to “rule out” a disease
(e.g., a PCT level of 0.1 µg/l to withhold antibiotic therapy
in infections of the respiratory tract [table 1]). In between
there is a grey zone where the biomarker alone does not add
sufficient information for a final ruling. Monitoring bio-
markers should mirror effectiveness of therapy for the pur-
pose of titration (e.g., BNP in the treatment of congestive
heart failure or PCT for antibiotic duration). Surrogate bio-
markers should correlate with clinical outcome in the set-
ting of an therapeutic intervention (e.g., HbA1c as surrog-
ate for complications of diabetes). Stratification or staging
biomarkers classify diseases based on outcome probability,
for example to limit side-effects of aggressive therapies to
high-risk patients with poor disease outcome if untreated
(e.g. D-dimer to exclude venous thromboembolism in need
for anticoagulant therapy in patients with a higher bleeding
risk). Companion biomarkers identify patients most likely
to benefit from a specific therapy (e.g. toxoplasmosis sero-
logy, quantiferon testing in HIV, HER2 positive breast can-
cer better selects women with breast cancer for treatment
with trastuzumab [Herceptin®])
Biomarkers should expedite the correct diagnosis and treat-
ment leading to personalised and tailored therapy [16] (fig.
1). In emergency patients with cardiorespiratory symp-
toms, patient history, clinical examination, chest radio-
graphs in conjunction with specific biomarker levels
provide important information useful for the fast and ac-
curate management of the patient. Point-of-care tests with
fast turnaround times can already deliver this information
in the prehospital setting including general practices and
ambulances which may further improve the management
of multimorbid and elderly patients with unspecific com-
plaints [17–20].
Biomarkers, may also improve site-of-care decisions which
are pivotal and major cost drivers. Decisions to hospitalise
patients admitted to the ED are often based on “gut-feel-
ing” of healthcare providers, patients or relatives rather
than objective clinical information. A recent survey in-
volving lower respiratory tract infection (LRTI) patients
revealed that, independently of expected mortality based
on pneumonia severity index or CURB-65 scoring, most
LRTI patients are hospitalised because physicians, nurses,
patients and relatives all believe that inpatient management
is indicated for medical reasons, particularly fear of severe
infection. Nursing reasons and patients’ and relatives’ per-
sonal preferences were mentioned to a lesser extent [21].
Clinical skills in emergency medicine – Osler’s “science
of uncertainty and art of probability”
As students we were taught to collect signs and symptoms
and try to fit them in a common physiopathological entity
characteristic of a particular disease. This systematic ap-
proach with thorough history-taking and physical exam-
ination allows one to combine the mosaic fragments of
cough, dyspnoea and/or chest pain to frame common clin-
ical diagnoses, such as ACS, pulmonary embolism, acute
heart failure (AHF) or CAP. Based on clinical reasoning we
initiate more or less specific and targeted therapies, such
as revascularisation, thrombolysis, diuretics or anti-micro-
bial drugs. This heuristic strategy, while being efficient,
relatively resource-sparing, and generally accurate, is not
without fail [22].
Seven decades ago, history-taking alone allowed the al-
legedly correct diagnosis known these days to be made in
74% of sick patients, usually in later stages of their disease
[23]. More recently, medical history and physical examina-
tion was presumed to yield a correct final diagnosis in more
than half of cases [24]. A Hawthorne bias makes these
study figures likely to be overly optimistic. Indeed, a more
recent analysis of dyspnoeic patients under ED conditions
revealed the correct diagnosis in only 41% after history tak-
ing, which was not improved after lung auscultation. Not-
ably, this number varied from 100% (smoke inhalation) to
less than 10% (chest wall pain) [25]. In real-life, clinical
performance depends largely on skills and experience, and
the quality of teaching and supervision of junior doctors
[22]. Senior physicians, are given little time or financial in-
centives for teaching duties and teaching is not an intuit-
ive endeavour for all physicians [26]. Sleep deprivation and
circadian rhythm disruption in doctors are strongly associ-
ated with human error and harm [27].
The clinical judgment even of experienced doctors can
be impaired by cognitive biases, such as availability, an-
choring, premature closure and framing. Physicians un-
derestimate their inter-person variability for clinical dia-
gnosis and overestimate their kappa (i.e., the agreement
with an independent colleague), even in the presentation
of allegedly “easy to diagnose” common diseases. [28]
For example, there is a dismal inter-physician agreement
about signs of chest examination: the kappas for cyanosis,
tachypnoea, and whispered pectoriloquy were only 36%,
25% and 11% (with 100% being perfect agreement) [29].
On average, medical patients are more than 70 years old on
hospital admission. Most emergency physicians have not
been trained in specific geriatric approaches, and many re-
port being less comfortable when dealing with older pa-
tients [30]. Masked (e.g., absence of fever) or unusual
presentation of disease in poly-morbid, elderly patients, or
limited patient cooperation (dementia, delirium, uncooper-
ativeness or deception) can be contributory [19].
Patterns of presenting complaints of patients vary in car-
diorespiratory diseases, including typical local symptoms
such as cough, at times productive, dyspnoea, chest pain to
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systemic moans such as fatigue, anorexia or myalgia [31].
Physical signs are not always present and, if present, may
be difficult to elicit when examining the chest [31]. Reports
on the validity of such signs have shown considerable dis-
agreement among physicians, leading to unreliable clinic-
al observations in cardiorespiratory diseases [29, 32, 33].
Indeed, clinical signs and symptoms show at best a mod-
erate helpful in the differential-diagnosis in patients with
acute dyspnoea [34]. Dullness to percussion, changes in
the intensity of breath sounds, and inspiratory crackles may
be present in a variety of pulmonary diseases that cause
lung stiffening, including AHF, pulmonary fibrosis and ob-
structive lung disease [25]. Presence of sputum or its dis-
colouring, dyspnoea, crackles, fever and increased white
blood cell count are insensitive and unspecific paramet-
ers for the diagnosis of bacterial LRTI requiring antibiotic
therapy [28, 35, 36].
Laboratory medicine and circulating biomarkers–
friend or foe to clinicians?
This review focuses on the use of readily available “per-
sonalised information” from biomarkers for improved dia-
gnosis and prognosis of common acute diseases, namely
cardiovascular and thromboembolic diseases, and infec-
tions. Biomarkers for which randomised controlled inter-
vention trials in the emergency setting are available were
selected.
Following emergency admission of patients with cardiores-
piratory complaints, history taking and physical examina-
tion result in a first list of differential diagnoses based on
subjective likelihood assumptions. For example, an afebrile
elderly patient presenting to the ED with dyspnoea as lead-
ing complaint, cough and pressure on the chest (or was it
pain?) might suffer from AHF, AMI, CAP with pleuritis or
even pulmonary embolism.
In the past, laboratory tests were used to identify organ and
system dysfunctions or diseases to confirm initial impres-
sions or rule out alternative diagnoses. While this is still
true, testing today is used more and more for prognost-
ication, risk stratification, site-of-care decisions to reduce
hospital readmissions [37–40]. Today, most cardiorespirat-
ory diagnoses are not considered final until after laboratory
testing is complete [41, 42].
The physicians’ increasing reliance on objective data from
diagnostic testing is arguably, at least in part, due to re-
duced or neglected history and physical examination skills
[26, 41]. Importantly, a skilled clinical judgment after fo-
cused history-taking and physical examination remains a
pre-requisite to minimise testing-related diagnostic errors.
Importantly, physicians should not make decisions based
upon one isolated finding, but rather on the overall gestalt
of the patient’s illness. Thereby, clinical reasoning is essen-
tial to determine the pre-test probability of a disease (i.e.,
prevalence), of treatment failure or complication and for
adequate interpretation of laboratory test results. As there
is ambiguity about what constitutes disease, more testing
will produce more “abnormal” findings, resulting in fur-
ther testing, which in the end makes patients sicker (and
poorer) [43]. It leads to unnecessary worries, procedures,
treatments and potentially unnecessary hospitalisations and
harm. Conversely, false negative test results lead to under-
estimation of disease status, delays and possibly worse out-
come [41].
The physician’s role in emergency medicine has changed
from clinical problem solving by history taking and exam-
ination alone to determine the pre- and post-test probabilit-
ies essential for the ordering and interpretation of laborat-
ory tests. Misapplication of test results can result from mis-
interpretation by the clinician – either from misunderstand-
ing the clinical implications of a result or from not under-
standing the limitations of the test methodology (i.e., stat-
istical variations, performance limitations, or interfering
substances) [41]. Therefore, clinical skills of experienced
physicians need to be synergised with modern biomarker
strategies knowing strengths and limitations of both.
Thanks to advances in quality control, diagnostic errors
today are rarely the result of an error in the analytical test
itself. Overall, it is estimated that laboratory results are
misleadingly wrong in 2%–4% of cases; roughly the same
error rates are found in diagnostic radiology [41]. Most
laboratory-related errors now originate from the pre-ana-
lytical and post-analytical processes, namely issues related
to the physician ordering and interpreting of test results.
Lapses in the reliable communication of abnormal labor-
atory and imaging results is a problem, even in systems
with advanced electronic medical records [41, 44]. In daily
routine the time between the initial clinician-patient en-
counter, test order, receipt of the sample by the laboratory,
the test result availability and clinician action based on res-
ults is considered too long by many. Point-of-care testing
should minimise testing-related delays provided the quality
of the assay, namely sensitivity, is not impaired [45, 46].
There is a true need of evidence-based medicine criteria in
laboratory medicine. The challenge to address for scientif-
ic investigators is the difficulty to design methodologically
rigorous randomised double blind trials without limiting
their validity for real-life, namely in the emergency setting.
Trials are performed on novel markers rather than estab-
lished markers. The established markers are mostly indir-
ectly tested as the control arm in studies investigating novel
markers. The superiority of the novel markers in such trials
may also result from the fact that patients in the biomarker
arm are treated and managed by standard operation proced-
ures whereas the control arms are mostly usual care. It may
hence be that these studies demonstrate the superiority of
patient management by standardized operating procedures
(SOP) rather than superiority of patient management by a
novel biomarker.
Physicians often disagree about what inappropriate laborat-
ory utilisation is [47]. Unfortunately, many “routine” labor-
atory tests are being ordered in “bundles” without any im-
pact on diagnostic or therapeutic management. This creates
needless traumas of venepuncture and unwarranted pre-
scriptions are a colossal waste of money – an unresolved
problem also at our own hospital. Many house staff contin-
ue to order recurring laboratory tests (“daily labs”). Mul-
tiple teams of physicians often consult on a single case,
write multiple sets of phlebotomy and laboratory orders
– often duplicated. Blood draws should not be considered
innocuous: up to 20% of hospitalised patients with acute
myocardial infarction suffered from phlebotomy-related
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hospital-acquired anaemia with an haemoglobin level of
<11 g/dl [48].
The elimination of unnecessary tests and procedures has
been identified as a key factor to reduce the trauma and ex-
penses of hospitalisation [49]. The American Board of In-
ternal Medicine’s “Choosing Wisely” campaign to reduce
unnecessary and potentially harmful tests is an important
first step [50]. Unbundling of tests, supervision by senior
physicians, feedback of individual phlebotomy-rates, and
warnings in electronic order entry systems lead to a reduc-
tion of phlebotomies of 20 to 60% [51, 52]. Unfortunately,
these laudable attempts are usually labour intensive and
short lived, initially promising effects disappearing shortly
after cessation of the educational effort [52]. Efforts incor-
porating education, requisition design, and funding incent-
ives have demonstrated the most durable effect [43].
Personalised triage in the ED using
risk scores & biomarkers
Hospital EDs are increasingly appreciated by patients for
their high-intensity medicine around the clock and are
overwhelmed by patients with both urgent and non-urgent
problems [53, 54]. This leads to overcrowded ED waiting
rooms with long waiting times. As a consequence, patients
truly needing urgent care may not be treated in time, where-
Figure 2
Systemic multiprofessional risk assessment for improve patient
management adapted from [261].
ProADM = proadrenomedullin
Figure 3
CURB-A score combining the traditional CURB-65 criteria with
levels of proADM to risk stratify site-of-care decisions in patients
with lower respiratory tract infections.
ICU = intensive care unit; ProADM = pro-adrenomedullin; SP =
Selbstpflege (self-care); PACD = post-acute care discharge
as patients with non-urgent problems may unnecessarily
receive expensive and oversized emergency care. Time to
effective treatment is among the key predictors for out-
comes across different medical conditions (“time is cure”),
including patients with AMI (“time is muscle”) [55], stroke
(“time is brain”) [56], CAP [57] and septicaemia (“surviv-
ing sepsis campaign”) [58]. In the latter case, early initi-
ation of fluid resuscitation and of appropriate anti-micro-
bial improves outcomes [59–62]. In contrast, other adjunct
sepsis therapies such as immuno-modulatory antibodies or
tight glucose control have not proven to be beneficial [63,
64].
Emergency medicine is under continuous pressure to im-
prove the value of healthcare services delivered. Physicians
have an obligation to their patients and to society in regard
to high quality, but also cost-effectiveness. The complexity
of increasingly multimorbid patients with acute exacerba-
tions of their chronic diseases is more challenging than
ever. Medicine has become more technical and complex
leading to system-related errors, such as technical failure,
equipment problems and organisational flaws.
For these reasons, an accurate and well-validated triage
system in the ED is pivotal for an optimal initial triage of
medical patients. ED triage should not only focus on treat-
ment priority, but also on site-of-care decisions (i.e., outpa-
tient versus inpatient management) and early identification
and organisation of post-acute care needs. An appropri-
ate risk assessment and subsequent triage is crucial for
an optimised patient care and allocation of limited health-
care resources. For this purpose, tools have been propag-
ated, namely standardised triage scores for the ED, nursing
scores to predict post-acute nursing care needs and bio-
markers thought to mirror physiopathological changes and
severity of disease (fig. 2).
Many patients prefer outpatient treatment [65]. Admission
rates and length of stay are affected by a variety of medical,
functional, psychosocial factors including patient and rel-
atives preferences [66–69]. Consecutively, despite a low-
risk according to clinical severity scores per se, many pa-
tients are still hospitalised for medical co-morbidities and
psychosocial reasons [66, 67].
Community-acquired LRTIs include acute bronchitis, acute
exacerbations of chronic obstructive pulmonary disease
and CAP. They are among the most frequent causes of hos-
pitalisation [70] and direct treatment costs amount to $15
billion in the USA [71]. Inpatient care of CAP is 8 to 20
times more expensive [66, 72] and carries a higher risk of
nosocomial infections including Clostridium difficile-asso-
ciated diarrhoea [73] than outpatient treatment. In the mul-
ticentre ProHOSP study, compliance with the PCT guided
antibiotic algorithm was 90% [74]. Importantly, only half
of the patients with LRTI in the low medical risk groups as
determined by PSI or CURB65 were treated as outpatients
despite high intensity implementation [74, 75]. Regardless
of low observed risk for adverse events, fear of medical
complications was the dominant motive for hospitalisation
similarly among physicians, nurses, patients and relatives
[21]. Thus, clinical severity scores, despite being recom-
mended in guidelines, have been insufficient in clinical ap-
plication due to complexity, problems memorising, but also
because of both relative insensitivity and non-specificity
Review article: Current opinion Swiss Med Wkly. 2015;145:w14079
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 24
Table 1: Commonly used biomarkers to personalise medicine in the emergency triage with indications and limitations.
Biomarker
Assay technique
Common
clinical
setting
Cut-off ranges (may be
assay specific)
Further
reading
Rule-in Caveats in ruling-in (false
high, impaired specificity)
Rule-out Caveats in ruling-out
(false low, impaired
sensitivity)
Proadrenomedullin
(ProADM)
Fluorescence
Immunoassay
Risk stratification
in respiratory
tract infections in
the ED
<0.75 μg/l low risk
0.75–1.5 μg/l intermediate
>1.5 μg/l high risk
[39]
[261]
[262]
[263]
More
intensified
monitoring and
treatment
Social and nursing aspects
of hospitalisation
Outpatient
treatment
Perceptions and
preferences of patient and
relatives
Other important
comorbidities
D-dimer
Highly sensitive
rapid ELISA,
nephelometric or
turbidimetric
assays
Venous
thromboembolism
(VTE)
<500 μg/l: no imaging if low
or intermediate (unlikely)
clinical probability for VTE
Imaging recommended if
≥500 μg/l independent of D-
dimer if high VTE
probability
Patients >50 years:
consider age-adapted cut-
off ranges:
cut-off = age x 10
[167]
[264]
Anticoagulation
if VTE ruled in
by imaging,
Age ≥80 years, all
conditions associated with
enhanced fibrin-turnover:
e.g., systemic inflammation,
vascular dissections,
infection, trauma, cancer,
pregnancy, inpatients
Consider
alternative
diagnosis to
VTE, e.g.,
aortic
dissection
High clinical probability for
VTE, upper-extremity deep
vein thrombosis, pregnancy
High sensitivity
cardiac troponin T
or I (hsTp)
hsTpT: e.g.,
electro-
chemieluminescent
immuno assay
(ECLIA)
hsTp I: e.g.,
luminescent
oxygen
channelling assay
(LOCI)
Suspected acute
coronary
infarction (AMI)
hs-cTnT
<14 ng/l low risk
14–52 ng/l intermediate
>52 ng/l high risk
[265,
266]
AMI Myocardial wall stretch and
cell necrosis of non-
ischaemic origin (e.g.,Tako
tsubo, pulmonary
embolism, myocarditis),
demand ischaemia (e.g.
sepsis) persistently
elevated level up to 14d,
renal failure
Consider
alternative
diagnosis to
AMI,
conservative
therapy of
symptoms
and
cardiovascular
risk factors
Time-lag of 1 to 3 h, rarely
circulating antibodies
against analyte
B-type natriuretic
peptide (BNP) or
N-terminal
fragment of BNP
(NT-BNP) or MR-
proANP
Luminescent
oxygen
channelling assay
(LOCI)
Dyspnoea and /
or suspected
acute heart
failure (AHF)
BNP:
<100 ng/l AHF unlikely
100–400 ng/l intermediate
>400 ng/l AHF likely
NT-BNP: <300 ng/l AHF
unlikely
3 age-dependent cut-offs
for rule-in of AHF (450, 900,
1800)
[131]
[136]
AHF Age, ACS, myocardial
hypertrophy, myocarditis,
pulmonary hypertension,
stroke
NT-BNP: renal failure
Consider
alternative
diagnosis to
AHF
Obesity, flash pulmonary
oedema, mitral valve
disease, pericardial
tamponade or constriction,
BNP: limited stability of
analyte
High sensitive C-
reactive protein
(hsCRP)
Nephelometric
assay, latex
enhanced
turbidimetry and
various
immunoassays
Cardiovascular
risk profiling
Inflammatory
status
Cardiovascular risk: <1 mg/
l: low
1–3 mg/l: intermediate
3.1–10 mg/l: high
Inflammatory status
<20 mg/l: low
20–50 mg/l: intermediate
>50 mg/l: high
[267,
268]
Cardiovascular
risk: Statins for
primary
prevention in
the GP setting
for antibiotic
stewardship in
RTIs
Inflammatory acute-phase
response of concomitant,
non-infectious disease (e.g.
SIRS, cancer,
thromboembolic disease)
SIRS Cardiovascular risk:
contribution of other
cardiovascular risk factors
Time-lag to peak response
(-72h),
steroids, hepatic failure
Procalcitonin
(PCT)
Fluorescence
immunoassay
Antibiotic
Stewardship in
Infections ,
namely of the
respiratory tract
in ED and
hospital ward
antibiotic
stewardship;
Infectious
aetiology of SIRS
in the ICU
ED & hospital ward:
<(0.1)–0.25 μg/l bacterial
infection (very) unlikely;
>0.25 (0.5) μg/l ng/ml
bacterial infection (very)
likely
ICU:
<(0.25)–0.5 bacterial
infection (very) unlikely;
>0.5 (1.0) ng/ml bacterial
infection(very) likely
[84]
[177]
[197]
Prescribe
antibiotics in
LRTI in the ED
and hospital
–ward setting.
In the ICU
setting
escalation of
antibiotic
therapy based
on serial PCT
measurement
not
recommended
New-borns, children,
severe trauma and
systemic inflammation
malaria, medullary thyroid
cancer and paraneoplastic
hormone production
Evaluate
alternative
diagnosis to
systemic
bacterial
infection,
discontinue
antibiotics in
LRTI and
sepsis,
Early-course (24h) , sub-
acute, and localised
infections,
insensitive assay, should be
applied in conjunction to
clinical improvement
AB = antibiotic; AHF = acute heart failure; ED = emergency department; GP = general practitioner; ICU = intensive care unit; PCT = procalcitonin; SIRS = systemic
inflammatory response syndrome; USA = United States of America; VAP = ventilator-associated pneumonia
for outcomes [76, 77]. Most deaths in patients with low risk
scores are non-CAP-related [76], and most causes of re-
admission within 30 days are due to co-morbidities (74%)
rather than CAP (20%) [78]. A further limitation of most
clinical risk scores for LRTI is that they are only validated
for CAP.
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Proadrenomedullin (ProADM) – “runner up” for a
more personalised site-of-care decisions
Adrenomedullin is a 52 amino acid polypeptide showing
sequence homology with other calcitonin-related peptides.
It was discovered 20 years ago as a secretion product of
a pheochromocytoma [79]. The adrenomedullin gene en-
codes for a 185 amino acid prepropeptide, post-transcrip-
tionally cleaved to produce the bioactive, amidated ad-
renomedullin. [80] Adrenomedullin, calcitonin-gene-re-
lated peptide (CGRP) and PCT belong to the same calciton-
in peptide superfamily and emerge from different CALC
genes with teleologically related, yet distinct physiopath-
ological molecular regulation and effects [81–84]. These
peptides are prototype “hormokines” which show beha-
viour of both hormones and cytokines and are ubiquitously
hyper-expressed during the host response to bacterial infec-
tions [85–87].
Adrenomedullin and other calcitonin-peptides compete for
binding to the same receptor family with agonistic and
antagonistic properties [83, 88]. They exert their effects
via G-coupled seven-transmembrane calcitonin receptor-
like receptor in association with RAMP2 or RAMP3 to
form the adrenomedullin receptors 1 and 2, respectively
[89, 90]. Upregulated by hypoxia, inflammatory cytokines,
bacterial products and shear stress, adrenomedullin acts
systemically and in autocrine and paracrine fashion [91,
92]. Adrenomedullin is a very potent vasodilating agent
believed to play a physiological role in arterial pressure
homeostasis with additional immune modulating and meta-
bolic properties [90, 93, 94]. Pleiotropic effects of ad-
renomedullin have been described: in tumour growth,
neovascularisation, endothelium protection, bronchodila-
tion, fertility, and immunity [95–99].
Adrenomedullin is found in plasma in health and at elev-
ated concentrations during various pathologic conditions,
including cardiovascular and renal disorders, sepsis, cancer
and diabetes [90]. Based on the hormone’s biological im-
portance and effects, the utility of measuring adrenomedul-
lin in blood seems evident. However, abundant binding to
peripheral and local receptors, a short half-life, and ex vivo
physical characteristics including instability and “sticki-
ness” make circulating adrenomedullin difficult to reliably
directly quantify [100, 101]. During adrenomedullin’s pro-
cessing into a mature hormone, it and an adjoining peptide,
mid-regional proadrenomedullin (MR-ProADM; referred
to here and elsewhere as proadrenomedullin [ProADM]),
are cleaved off of the precursor in a 1:1 ratio. This stoi-
chiometric secretion, the peptide’s apparently minimal if
any biological activity and hence, binding, and it’s consid-
erable chemical stability render ProADM an easily and ro-
bustly quantifiable surrogate biomarker for adrenomedul-
lin [100, 102, 103]. ProADM has been used as a prognostic
marker, alone or in risk stratification with other hormonal
propeptides in patients with sepsis and severe pneumonia
[82, 104, 105].
Adding prognostic biomarkers to a thorough clinical and
interdisciplinary assessment bundles may allow detecting
subgroups of patients with higher than anticipated risk re-
quiring expedited assessment, intensified care and monitor-
ing. Conversely, the prediction of a very low risk of adverse
events by both interdisciplinary assessment and biomark-
er embedded in a system of risk-appropriate sites of care
(e.g. nurse-led care NLC), structured discharge planning,
patient education and immediate follow-up and an anticip-
ated lower risk of healthcare associated infections [106]
should provide sufficient confidence for physicians, nurses,
patients and relatives in our risk-adapted triage with exped-
ited discharge planning. Also, prognostic markers may help
to select specific medical therapies for patients most likely
benefiting from them, namely in resource-deprived settings
(e.g., busy shifts and/or shortage of ED staffing).
Multiple “promising” prognostic biomarkers have been
proposed in observational studies. Yet, the clinical efficacy
and safety of their use for prognostication needs to be es-
tablished in randomised-controlled intervention studies. C-
reactive protein (CRP), PCT and other routinely measured
markers have at best a moderate prognostic utility in sys-
temic infections and other diseases [105, 107–109]. Thus,
they cannot be used for site-of-care decisions. For pro-
gnostic purposes, ProADM has proven to be superior to
CRP, PCT or any other of the plethora of marker from dif-
ferent biological pathways [105, 110–112]. In patients with
CAP and other LRTI, proADM levels measured on admis-
sion were significantly associated with disease severity and
fatal outcome [93, 111] ProADM had a superior prognost-
ic value for predicting complications in LRTI compared
to guideline-recommended clinical severity scores [104,
105, 113–120]. The combination of biomarkers and clinical
scores (i.e., CURB65 and PSI) provided superior prognost-
ic accuracy providing an additional margin of safety [105,
116, 117, 119, 121]. Consequently, an improved assess-
ment of LRTI has been proposed based on CURB-65 and
ProADM cut-off levels where patients were stratified in-
to three risk classes with estimated mortality rates ranging
from 0.65% to 9.8% (fig. 3) [121]. In a recent randomised-
controlled pilot study this combined algorithm tended to
reduce hospital length of stay without negatively affecting
patient outcomes compared to patients stratified according
to CURB-65 alone [40]. These results must be interpreted
in light of unresolved organisational challenges in dis-
charge planning and availability of beds in nursing homes
and other post-acute care settings beds.
In the current society, patients and physicians are risk-
averse and appear to prefer objective risk numbers com-
pared to more complex clinical algorithms. Herein,
ProADM alone or in combination with a prognostic bio-
marker bundle has the potential to enhance the interdis-
ciplinary risk assessment and may improve the currently
limited compliance with existing guidelines. This may also
provide a more individualised and comprehensive risk as-
sessment. Prognostic biomarkers may facilitate selection of
patients for whom early discharge is safe and may help to
focus resources to the patients in need. Prognostic biomark-
ers may help physicians to identify patients who would,
and would not, benefit from distinct therapies and thus may
allow a transition from bundled care to more personalised
approaches, which in turn could result in improved patient
outcomes.
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Personalised medicine in cardiology
Cardiac troponin (cTn) in AMI
Acute myocardial infarction (AMI) is the cause of death in
more persons worldwide than any other disease [122, 123].
With effective treatment in our hands, accurate and rapid
diagnosis is of major medical and economic importance.
In the initial assessment, electrocardiography (ECG) is of
paramount importance to detect diagnostic ST-elevations
which require immediate transfer to a catheter lab. There
is no need to wait for the biomarker results. Still, cardiac
troponin is measured to use it to 1) determine infarct size
and 2) definitely prove that an AMI has occurred. Also, not
all ST-elevations are unequivocal, as multiple causes other
than STEMI might lead to ST-segment elevations such as
left ventricular hypertrophy, myocarditis, takostubo cardi-
omyopathy, and unknown causes as in healthy young men
[124]. In suspected unstable angina and non-ST-elevation
myocardial infarction (NSTEMI) cardiac troponins are in-
deed mandatory in all patients to decrease the diagnostic
ambiguity of the clinical diagnosis. In a study setting, ex-
perienced primary care physicians correctly classified 88%
of low-risk walk-in patients with chest pain as having either
an organic or non-organic aetiology solely on the basis of
their initial clinical judgment and before ordering any dia-
gnostic tests [125]. In an ED setting with multimorbid pa-
tients and a higher pre-test probability for organic disease
the ambiguity of clinical findings is much higher, for ex-
ample >90% in a real-life study under emergency condi-
tions [25]. Therefore, cTn testing is recommended by all
current guidelines to improve clinical performance.
With the development of sensitive assays depicting either
cTnI or cTnT (the only current biomarkers thought to be
unique to the heart) the diagnosis of AMI was revolution-
ised [123, 126–128]. In a patient presenting with chest
pain, a rise in cTn has become a conditio sine qua non for
the clinical diagnosis of AMI. Cardiac troponins are our
current gold standard for the detection of myocardial nec-
rosis. The more sensitive the cTn assay used, the smaller
the number of dying myocardial cells necessary for this sig-
nal to get detected. This has enabled patients to be detected
even with very small AMIs. It also allows more rapid de-
tection of AMI (usually within 1 or 2h if high-sensitivity
cTn assays are used) [127]. Overall, high-sensitivity cTn
assays seem to constitute a major medical and economic
improvement in clinical practice.
However, the clinical use of these assays has created also
challenges and uncertainties: It is unclear, whether the
medical benefit observed in previous RCTs for early re-
vascularisation and aggressive antiplatelet therapy also ap-
plies to patients with very small AMIs. As these patients
still seem to be at an increased risk of death as compared
to patients without elevated high-sensitivity cTn levels, the
current ESC guidelines encourage us to do so [122, 123,
126–128]. Secondly, myocardial damage is not restricted
to AMI, but may also accompany other medical conditions
like septic shock, pulmonary embolism, hypertensive heart
disease accompanying end-stage kidney disease, or acute
heart failure. As we currently lack a biomarker that reliably
detects plaque rupture or coronary thrombosis, we are often
left with our basic clinical tools including patient history
to differentiate AMI from other causes of myocardial dam-
age. The interpretation of cardiac troponin as a quantitat-
ive marker of cardiomyocyte damage, where the likelihood
for the presence of AMI increases with increasing levels
of cardiac troponin, and the use of absolute changes within
1–3h as complimentary information to distinguish causes
of chronic elevations such as heart failure (usually not
showing relevant short-term changes) from causes leading
to acute cardiomyocyte damage such as AMI, which are as-
sociated with a rise and/or fall. Third, once a diagnostic test
is declared “gold standard”, it becomes practically impos-
sible to definitely rule out false positive test results. This is
currently the case with cTn. We strongly think that the heart
is invariably the exclusive source of cTn elevations, regard-
less of the specific patient condition. However, as both the
ECG and imaging techniques have by far lower sensitiv-
ity for myocardial necrosis as cTn, scientific proof often
cannot be delivered in an individual patient. One easy op-
tion to exclude analytical false-positive levels is to measure
a second cTn assay (e.g. cTnI when initially using cTnT).
Fourth, despite the introduction of highly sensitive assays,
follow-up measurements after 3 hours are needed to ex-
clude AMI, which may delay time to ED-discharge. The
use of assay-specific early algorithms [129], or the combin-
ation of cardiac troponin with copeptin, seem to allow an
even earlier rule-out [130].
Natriuretic peptides (ANP, BNP) in heart failure
For example, in a meta-analysis identifying the symptoms,
signs, and tests most useful in diagnosing acute heart fail-
ure (AHF), no single history-taking or physical examina-
tion findings provided adequate discrimination [131]. The
most discerning features of AHF – such as the presence of
paroxysmal nocturnal dyspnoea, an S3 gallop, or jugular
venous distention – have such a low incidence (each docu-
mented in <50% of patients with AHF) that their sensitiv-
ity for the diagnosis of AMF is low. In fact, the best single
predictor of AHF was found to be a B-type natriuretic pep-
tide (BNP) value of 250 ng/l with a sensitivity of 89% and
a specificity of 81%. Nevertheless, high initial clinical sus-
picion (based upon the complete history and physical) was
the most predictive element in the diagnosis of AHF. These
observations highlight the need to interpret BNP levels as
quantitative markers of hemodynamic cardiac stress. Low
levels (<100 ng/l) are helpful for the rule-out of AHF as
the cause of acute dyspnoea, while high levels (>400 ng/
l) are helpful for rule-in of AHF. Based on data from sev-
eral RCTs, natriuretic peptides (BNP, NT-proBNP, or MR-
ProANP) should be obtained in all patients presenting with
acute dyspnoea to the ED.
Accurate biomarkers of heart failure are highly desirable
tools for physicians to either improve their ability make an
early and accurate diagnosis or to follow positive or negat-
ive changes as a result of therapeutic intervention. The abil-
ity of physicians to make earlier diagnoses is valuable be-
cause therapeutic interventions are available that can make
a significant impact on patient quality of life and cost of
care [16, 132–137]. Annual costs of heart failure in Europe
and the United States are estimated at $130 billion, 70%
of which is due to hospitalisation. Half of heart failure pa-
tients are re-admitted within 6 months and 10% are re-ad-
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mitted twice with heart failure [16, 134]. Fewer re-admis-
sions by guided therapy methods could significantly impact
the costs associated with this prevalent disease. All three
clinically available natriuretic peptides (BNP, NT-proBNP,
or MR-ProANP) seem to have similar diagnostic accuracy
in this indication [16, 38, 132–143]. In addition, natriur-
etic peptides, as quantitative markers of heart failure that
summarise the extent of systolic and diastolic left ventricu-
lar dysfunction, valvular dysfunction, and right ventricu-
lar dysfunction [136], provide valuable information for risk
stratification in patients with acute and chronic heart failure
[38, 140–143]. Although still under some debate, BNP and
NT-proBNP measurements also seem capable of improv-
ing the long-term management of patients with chronic HF
[141, 142]. Detailed recommendations on how to best ap-
ply these biomarkers have recently been provided in this
journal [136]. Appropriate cut-off values have been defined
in large observational studies, and evidence from large ran-
domised controlled studies confirms both medical and eco-
nomic benefit from their use.
The use of natriuretic peptides shares one important chal-
lenge comparable to that of cTn: Having become the most
sensitive test to detect a disorder (heart failure), other cur-
rent clinically available methods including cardiac imaging
have a major limitation in the clarification of unexpected
and potential “false positive” elevations of natriuretic pep-
tides. Again, one easy option to exclude analytical false-
positive levels is to measure a second natriuretic peptide
(e.g. NT-proBNP when initially using BNP).
Personalised medicine in venous
thromboembolism
D-dimers
For many years, the diagnosis or exclusion of acute venous
thromboembolism (VTE), defined as deep leg vein throm-
bosis and/or pulmonary embolism, often relied on invasive
and costly imaging techniques, such IV venography and
pulmonary angiography. As VTE was confirmed in only
about one third of patients in whom it was suspected [144,
145], the development of non-invasive exclusionary tests
became necessary. D-dimer, a cross-linked fibrin degrada-
tion product, is an indicator of coagulation activation and
fibrinolysis and can be measured in both whole blood and
plasma [146]. More than 25 years ago, D-dimer testing
using quantitative enzyme-linked immunosorbent (ELISA)
D-dimer assays was found to be highly sensitive for the
detection of VTE (sensitivity ≥95%) [147–149]. Today, a
variety of commercial D-dimer assays are available. The
main assay categories include quantitative, fully automated
rapid ELISA or immunoturbidimetric latex-agglutination
assays with a high sensitivity (96%–99%) but a rather low
specificity (38%–48%) and qualitative or semi-quantitative
latex agglutination and whole-blood point-of-care tests
with a moderate sensitivity (69%–85%) but a higher speci-
ficity (68%–99%) [146, 150].
Since the 1990s, prospective management studies have
demonstrated that it is safe to withhold anticoagulation in
patients with a low/intermediate or unlikely clinical prob-
ability of VTE based on clinical scores (e.g., Wells scores,
revised Geneva score) and a negative highly sensitive D-
dimer test (e.g., rapid ELISA), precluding the need for
further imaging [151, 152]. If a less sensitive D-dimer
test is used (e.g., whole-blood agglutination assay), it is
still safe to withhold anticoagulation in patients with a
low or unlikely probability of VTE [151, 153–155]. It has
been estimated that by assessing patients according to this
strategy, at least a 30% decrease in diagnostic imaging can
be achieved in outpatients with suspected VTE, resulting
in less waiting time and diminished costs of care [154].
These results have been corroborated by randomised clin-
ical trials [156, 157]. Practice guidelines recommend initial
D-dimer testing when evaluating patients with either a low
(with either a moderately or highly sensitive D-dimer test)
or moderate clinical probability (highly sensitive D-dimer
only) of VTE [8, 158]. If the D-dimer test is negative, VTE
is considered excluded and no further imaging, such as
compression sonography or spiral computed tomography,
is necessary. A positive D-dimer should be followed by
imaging. As it is not clear whether D-dimer tests can safely
rule out VTE in patients with a high clinical probability,
initial testing with imaging (without D-dimer testing) is re-
commended. The Choosing Wisely campaign, launched by
the American Board of Internal Medicine Foundation to
avoid overuse, recommends not to order computed tomo-
graphy to diagnose pulmonary embolism without initial
risk stratification (pre-test probability and D-dimer tests if
low probability) [159].
Despite its potential to avoid imaging, D-dimer testing is
hampered by several practical limitations. D-dimer tests
suffer from a lack of standardisation, results (and cut-off
points) are not comparable between different assays. As the
ability to exclude VTE depends on test sensitivity, clini-
cians should be aware of the specific assay used at their
institution and its test performance characteristics [146].
A major problem of D-dimer is the lack of specificity for
VTE, leading to a high rate of false positive results. El-
evated D-dimer levels can be found in any condition as-
sociated with enhanced fibrin formation and fibrinolysis,
including surgery, trauma, infection, pregnancy, cancer,
myocardial infarction, stroke, atrial fibrillation, inflammat-
ory conditions, and advanced age [146]. For instance, while
about one third of unselected outpatients with suspected
pulmonary embolism have a negative rapid ELISA D-di-
mer test (conventional cut-off 500 μg/l), this proportion de-
creases to 5% in patients aged ≥80 years, 11% in patients
with cancer, and 4% of inpatients [160–162], which greatly
reduces the efficiency and clinical usefulness of D-dimer
as an exclusionary test in these populations. The safety of
D-dimer testing to exclude VTE in special situations, such
as pregnancy or upper extremity deep vein thrombosis, has
not been examined in prospective management studies and
therefore, the role of D-dimer testing is yet to be determin-
ed in such patients.
Although D-dimer testing was originally developed to re-
duce unnecessary imaging, an increasing use of D-dimer
does not decrease or even increases referrals for VTE-re-
lated imaging in the real-life setting [163, 164]. Potential
underlying reasons are the indiscriminate use of D-dimer
because of its easy availability (together with modern ima-
ging techniques, such as multidetector spiral computed
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tomography) and a declining tolerance to diagnostic uncer-
tainty [154]. Attempts have been made to resolve this issue
by better selecting patients requiring D-dimer testing for
pulmonary embolism using explicit clinical criteria (PERC
rule) [165, 166]. Recently, to increase the specificity of
highly sensitive D-dimer assays in patients aged ≥50 years,
the utilisation of an age-adjusted cut-off value (cut-off =
age x 10) was successfully validated in a large prospective
management study [167]. Finally, the clinical value of D-
dimer testing in specific populations, such as pregnant wo-
men or patients with upper extremity deep vein thrombosis,
must be validated in prospective management studies be-
fore its use can be recommended in these populations.
Personalised medicine in
inflammatory and infectious diseases
Inflammatory toxins, immunogenic antigens, infectious
pathogens, and mediators of the host response all stimulate
pro- and anti-inflammatory mediators and coordinate re-
cruitment of immune cells to the acute site(s) characteristic
for the diseases. Precursors, mature forms and degradation
products of mediators involved, penetrate from the original
site of action into the circulation. As surrogate blood bio-
markers these substances mirror the extent and severity of
the insult. Numerous attempts have tried to correlate these
different mediators with the presence and course of disease
as diagnostic and prognostic markers.
Like in other disease states, ED physicians face the di-
lemma of ambiguous clinical manifestations of infectious
and inflammatory diseases at emergency presentation.
Inflammation-related cognitive impairment may worsen
the value of history-taking. Multimorbidity further masks
typical textbook signs and symptoms of infections or
makes their presence ambiguous [168]. Even in patients
with typical bacterial CAP the classical sign of fever is ab-
sent in almost half of hospitalised patients [28]. A posit-
ive culture result of a bacterial pathogen in bodily fluids
is considered ultimate diagnostic proof for bacterial infec-
tion or sepsis by many. Indeed, the possibility for resist-
ance testing argues for routine sampling of (blood) cul-
tures and is life-saving in a setting with prevalent mul-
tiresistance. Clinicians, therefore, order blood cultures lib-
erally if bacteraemia is suspected, for example when pa-
tients have fever, chills, leucocytosis, signs of focal in-
fections, indications of sepsis, or suspected endocarditis
prior to starting parenteral anti-microbial therapy. Unfortu-
nately, these criteria are unreliable and clinical prediction
rules lack external validity and are complex with use of
difficult-to-obtain variables [169]. Hence, only a small pro-
portion (4%‒7%) of blood cultures yield true-positive res-
ults [169–171]. Of these, as many as half represent contam-
inants, i.e. false-positives which may unnecessarily expand
investigations and extend hospital stay [172]. Hence, order-
ing blood cultures without appropriate pre-test probability
criteria is both wasteful and harmful [173, 174].
In the pre-antibiotic era, mortality from pneumococcal
CAP was between 20 and 30% overall, rising to more than
60% for bacteraemic cases [175]. Today with antibiotics,
mortality in patients hospitalised for CAP is between 5% to
10%, dependent on co-morbidity [74], and in septic shock
rise still up to 50% [87]. Earlier administration of anti-
biotic therapy improves outcomes in patients with severe
sepsis [60]. The current sepsis guidelines, therefore, have a
strong recommendation for administering antibiotics with-
in 1 hour of the diagnosis (or suspicion) of severe sepsis.
[62] Yet, not all patients with clinical signs of infection –
including SIRS criteria – truly have a bacterial infection
in need of antibiotic therapy for cure. Beneficial effects of
empiric antibiotic therapy must be weighed against their
harmful effects particularly in regard to emergence of drug-
resistant bacteria and other drug-related side effects [176].
Biomarkers may allow transformation of bundled sepsis
care to more personalised patient management [177, 178].
The recognition over 25 years ago that the host response
plays an exquisite role in sepsis led to the definition of
sepsis that is still the standard today [62]. Unfortunately,
the systemic inflammatory response syndrome (SIRS) vari-
ables (i.e., body temperature, heart rate, tachypnoea, white
blood count) turned out to be ambiguous, lacking sensitiv-
ity, specificity and ease of clinical application [179]. Thus,
a gold standard to differentiate bacterial from non-bacterial
or non-infectious causes in patients with SIRS does not ex-
ist, and thus all observational studies are prone to a poten-
tial bias. As long as patients with the slightest suspicion of
(bacterial) infection are treated with antibiotics “just to be
safe”, all observational diagnostic studies are biased due to
the lack of independent comparison with a true gold-stand-
ard for a relevant bacterial aetiology in true need of anti-
microbial therapy. This dilemma can, unfortunately, not
be resolved by meta-analysing a selections of inherently
flawed observational studies since most patients in those
studies were in fact treated with antibiotics despite the low
pre-test probability for an infection [180–182]. Indeed, the
potential to change clinical decision making is the most im-
portant performance measure for a biomarker. Therefore,
randomised intervention studies have to be done in which
the anti-microbial therapy is guided by a biomarker and in
which the primary measure of efficacy is outcome [176].
If the patient recovers without antibiotics, there was ob-
viously no serious bacterial illness in need of antimicro-
bial therapy. Herein, we discuss the two biomarkers CRP
and PCT for which several randomised intervention stud-
ies have been published. CRP has become a de facto “uni-
versal inflammatory screening marker” in clinical routine
(table 1). Considering the greater sensitivity and specificity
demonstrated in an impressive body of literature PCT can
reduce the limitation of the SIRS staging in sepsis and im-
prove guidance of anti-microbial therapy [177]. Although
far from being a perfect marker [180], PCT improves the
accuracy of the clinical diagnosis in hospitalised patients
with infections of the respiratory tract and sepsis [28, 35,
183]. In contrast to CRP and other biomarkers, circulating
PCT levels are not affected by steroid co-medication [184,
269]. Accordingly, it has been included in the PIRO staging
system for sepsis, which includes the predisposition, infec-
tion, response and organ failure [185].
Detection of subtle, sub-acute inflammation with C-
reactive Protein (CRP)
CRP is an acute phase reactant whose synthesis in the liver
is up-regulated by IL-6 in response to inflammation inde-
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pendent of the aetiology. CRP has a role in the clearance
of dying and altered cells, and might also have more com-
plex immuno-modulatory functions. Recent evidence sug-
gests that the genetic variants influencing basal CRP level
also influence the magnitude of the acute-phase rise in CRP
level in active inflammation. These genetic effects might
be large enough to directly influence clinical decision-mak-
ing processes that are based on an interpretation of CRP
thresholds [14, 186].
As a biomarker CRP has been used for decades in Europe
to screen for the presence of significant inflammatory or in-
fectious disease in the ED [187]. Its advantages include the
relatively low pricing in routine labs, widespread availabil-
ity also for general practitioners as point-of-care tests and
high sensitivity even for low grade and chronic systemic
inflammation.
Indeed, as a sensitive marker of subtle, sub-acute vascular
systemic inflammation, measurements of high-sensitivity
CRP (hs-CRP) plasma levels add to both the prognostic in-
formation gleaned from assay of plasma lipid risk factors
and the risk levels estimated by means of Framingham
study– based criteria [188–190]. A large-scale, randomized
clinical trial – Justification for the Use of Statins in Primary
Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) – demonstrated that potent statin therapy re-
duces the risk of heart attack and stroke by 50% among
men and women with low levels of LDL-cholesterol who
are at increased vascular risk mirrored by elevated levels of
CRP [191].
Every year there are millions of visits to primary care phys-
icians by adults with a chief of complaint of cough, repres-
enting over 5% of all visits to physicians. To determine the
aetiology of infections of the respiratory tract history and
prescribe antibiotic therapy, history and physical examina-
tion are misleading [28, 31, 35], which leads to antibiotic
over-prescription “just to be safe”. In acute bronchitis, the
antibiotic prescription rate should be zero. Despite years
of intensive and internationally concerted efforts, in the
US the rate hovers around 70% both in primary care and
EDs. [192] Factors such as diagnostic ambiguity about pos-
sible bacterial infection, avoidance of potential risks with
legal consequences, and patient demands play an import-
ant role. Prescription rates of antibiotics was lowered in
a study-setting by around 10% by a clinical decision sup-
port system [193]. Unfortunately, this effect is only mod-
est and not persistent. Together with measures to enhance
communication-skills of general practitioners as point-of-
care test CRP reduced antibiotic overuse in mild and usu-
ally self-limiting respiratory tract infections by 30 to 40%
[194, 195].
Unfortunately, in more poly-morbid and severely ill, and
thus more inflamed patients admitted to the ED, CRP ten-
ded to increase antibiotic prescriptions for acute cough ill-
ness when compared to a clinical algorithm [196]. A low
specificity, delayed dynamics and attenuated rise by con-
comitant steroid medication are important drawbacks of
CRP as a biomarker in systemic and more peracute in-
fections (sepsis) especially in the presence of poly-mor-
bidity, which is omnipresent in hospitalised patients [84,
197]. Many physicians use it in hospitalised patients for the
follow up of infectious diseases, despite CRPs drawbacks
and misleads as marker, for example in LRTI admitted to
the ED, [117] hospitalised CAP [28, 105], COPD [198] or
sepsis [104].
Despite these limitations in the hospital setting, CRP is
bundled in countless “admission labs”. This despite the
lack of any guidelines to recommend this (mis-)use and no
consequences for the decision-making or therapeutic pro-
cess. Once established as a “standard of laboratory care”
for admission and hospital follow-up, it is almost impos-
sible to not use it in clinical routine. As a contagious labor-
atory disease artefact this leads directly or indirectly to ad-
ditional investigations to differentiate the alleged “CRPit-
is”. This exemplifies the dilemma for biomarkers, that we
are rapid in adopting new measures but reluctant to stop
measuring them once we have got used to it. Another po-
tential target for the “choosing wisely” of the American
College of Physicians campaign?
Procalcitonin to de-escalate anti-microbial treatment
and sampling of blood cultures in infections of the
respiratory tract and sepsis
In systemic infections, calcitonin (CALC) genes are ubi-
quitously expressed in parenchymal cells and, in essence,
the entire body becomes an endocrine organ [90, 199].
PCT, a CALC-I gene product, is stimulated synergistically
by the inflammatory mediators of host response (e.g., inter-
leukin (IL)-1β, tumour-necrosis factor (TNF)-α, and IL-6),
bacterial products (e.g., [LPS (lipopolysaccharide)], lipo-
techoic acid) and necrotic body cells [81, 199–202]. This
typically occurs following external infection with bacterial
micro-organisms. Bacterial translocation triggered across
the gut wall by gastrointestinal malperfusion may trigger
a similar cascade, which explains why circulating PCT in-
crease both during septic and cardiogenic shock [203, 204].
PCT is the prototype of a hormokine mediator, sharing bio-
logical characteristics of both, hormones and cytokines [83,
205]. It circulates as 114 amino acid, lacking the N-termin-
al dipeptide alanine-proline [90]. Historically, a hormon-
al function of calcitonin peptides was alluded to calcium
homeostasis and bone metabolism [90, 206, 207]. Today,
they are thought to adapt metabolism and vascular tone
to acute needs in inflammation [81, 93], to combat invad-
ing microbes during exogenous infections [208], to modu-
late migration and phagocytic activity of neutrophils, and
to locally increase in pro-inflammatory cytokines and NO
[90]. PCT modulates the action of other members of the
calcitonin peptide superfamily, including CGRP (calcitonin
gene-related peptide), ADM (adrenomedullin) and amylin
[88]. The several 100’000–fold increased PCT levels nulli-
fy their activities, effects that likely are beneficial in this ill-
ness. Accordingly, administration of recombinant PCT pro-
tein to septic hamsters with peritonitis doubled their death
rate [209]. Conversely, treatment with antiserum reactive
against calcitonin precursors increased survival in mono-
and polymicrobial sepsis in three animal models (hamster,
rats and pigs) [209–212].
Unfortunately, PCT (aka “immune-reactive calcitonin”)
was initially propagated as a dichotomous diagnostic and
prognostic biomarker for critically-ill patients with pancre-
atitis [213] and toxic shock syndrome associated with hy-
pocalcaemia, [214] burns and lung injury [215, 216], men-
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ingitis in children [217, 218], neonatal infections [219] and
adult sepsis in intensive care units [87, 220, 221]. Superior
to other biomarkers, PCT appeared to improve the clinic-
al diagnosis of sepsis in critically ill patients [183]. At that
time, sepsis was ill-defined as the presence (probable or
documented) of infection together with systemic manifest-
ations of inflammation [62, 179]. The consequent ambigu-
ities in interpretation of different cohorts and settings pre-
cluded an undisputed sentence on the utility of PCT in the
intensive care setting [180, 197, 222, 223]. PCT’s kinetic
profile shows a prompt increase within 6–12 hours of infec-
tion and circulating PCT levels are cut in half daily when
the infection is controlled [224]. PCT correlated with bac-
terial load [171, 173, 225] and severity of infection and out-
come [226–228]. PCT offers additional prognostic inform-
ation in high-risk patients as an adjunct to existing rules
[229]. An increase of PCT suggested early identification of
moribund critically ill patients despite being on antibiotic
therapy [230]. A subsequent large ICU based multicentre
PASS-trial, however, documented deleterious effects when
antibiotics and diagnostic measures were escalated based
on increasing PCT levels >1 ng/ml in patients for whom
infection may not have been the main problem necessitat-
ing ICU admission [231]. In this study, measurement PCT
was delayed as samples had to be shipped hundreds of kilo-
metres to a central study laboratory. Protocol-driven there
were more investigational procedures, increased side-ef-
fects of intensified antibiotic treatment and organ-related
harm resulting in a prolonged stay in the intensive care unit
[231]. The antibiotic escalation strategy like the one used
in the PASS-trial can definitely not be recommended in a
setting with a high baseline antibiotic exposure, such as an
ICU in Denmark [232].
Conversely, a more rational antibiotic de-escalation
strategy in critically-ill patients with suspected sepsis syn-
drome on antimicrobial therapy using adapted cut-off
ranges proved to be safe and effective with 25% reduction
of antibiotic exposure in the large multicentre PRORATA
study in France [233].
To date, the efficacy and safety of PCT protocols to de-
escalate antibiotic overuse has been demonstrated in more
than 14 randomised, controlled trials in different clinical
settings and including infections of varying severity [177,
234, 235]. The respiratory tract is the most common ori-
ginal site of bacterial sepsis [87]. Over 90% of all respir-
atory infections are initially presumed to be of single or
even multiple viral origin [236]. Interestingly, cellular up-
regulation of PCT is attenuated by cytokines released in re-
sponse to viral infections, such as interferon-gamma (INF-
γ) [201]. ICU studies including patients with only viral or
both viral and bacterial CAP during the H1N1 outbreak
found higher PCT levels in the latter group [237–239].
The PCT de-escalation protocols used were similar and all
based on the same intuitive concept: recommendations for
or against initiation or continuation of antibiotic therapy
was based on initial PCT levels, the kinetics of PCT over
time, or both, as well as the clinical picture of the patient
[74]. The cut-off ranges differed depending on the clinical
setting and the acuity of presentation [234]. These pro-
tocols proved to be safe and highly effective in terms of
lowering antibiotic exposure. In fact, for low-severity pa-
tients, such as bronchitis and upper respiratory infections in
general practice, prescription rates lowered by 60%–70%
were found [177, 234, 235]. In the ED, antibiotic initiation
was reduced by almost 50% in severe lower respiratory
tract infections and 60% in severe exacerbations of COPD
patients with need for hospitalisation [240, 241]. Of note,
all these studies were done in settings with a very low an-
tibiotic prescription rate in the control group. Thus, the ef-
fect would even more pronounced in countries with higher
antibiotic exposure and resistance rates. In higher-severity
patients, PCT guidance resulted in a relative reduction in
the duration of antibiotic treatment by 40% in CAP and by
25% in the critical care setting [233, 242]. PCT-guide de-
escalation of empirical antibiotic therapy resulted in lower
medication costs, antibiotic side effects and adverse out-
comes [5, 74].
Can these data, mostly obtained in hospitalised patients
with respiratory tract infections, be indiscriminately ap-
plied to other sites of infection, to all age groups or sepsis
in general? Clearly, NO! Community-acquired respiratory
tract infections are relatively homogenous; a prerequisite
that the procalcitonin algorithm actually worked. Indeed,
“sepsis” is merely an ill-defined, heterogeneous clinical
syndrome [243]. PCT can merely complement a physician
and the clinical judgment on the probable site and source of
infection will always remain a fundament for patient care.
Therefore, the host response and optimal cut-off ranges for
PCT vary with underlying illness, co-morbidity and im-
mune status of the patients as well as the source and vir-
ulence of initial infection, such as meningitis, endocarditis,
abdominal, urinary tract, catheter related or nosocomial in-
fections [46]. Cut-off ranges have to be calculated by mul-
tilevel likelihood ratios and adapted to different settings
and types of infection. Rapid and appropriately sensitive
assays are to be used [45, 46, 244].
For example, the cut-off used in adults has been shown to
be too low for children with a more reactive immune sys-
tem [245, 246]. In new-borns there is even a physiologic-
al rise within the first postnatal days, presumed to be as-
sociated with intestinal bacterial colonisation [247, 248]. If
the cut-off is adapted accordingly, PCT becomes a reliable
marker to diagnose neonatal infections [249]. In a pilot-
study from France, a PCT level of <0.5 ng/ml was used
to avoid unnecessary antibiotics and hospitalisation in chil-
dren during an outbreak of viral meningitis [250].
PCT reflects severity of renal lesions in pyelonephritis
[251] and bacteremia and bacterial load and in the
urosepsis syndrome [225]. Guidelines on the duration of
antibiotic therapy are largely based on expert opinion only,
therefore infections of the urinary tract are another target
for PCT-guided stewardship [252]. Indeed, together with
the resolution of pyuria [253], Combined pyuria and PCT
guidance led to a 40% reduction of mean antibiotic expos-
ure in a recent randomised pilot study [254].
In patients with suspected bloodstream infections, the ae-
tiology of a presumed “bacterial” cause of fever cannot be
detected in 50–80% [171, 173, 174, 255]. Clinicians or-
der blood cultures liberally in patients admitted for CAP in
the ED though they are costly and less than 5% of blood
cultures yield true-positive results which change anti-mi-
crobial therapy [169]. PCT levels on admission accurately
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predict later blood culture positivity in immunocompetent
patients with CAP. A PCT cut-off of 0.1, 0.25 or 0.5 mg/l
would enable reduction of the total number of blood cul-
tures by 13, 37 or 52% and still identify 99, 96 or 88%, re-
spectively of positive blood cultures in CAP [171]. These
figures are superior to clinical decision rules, which have
practical limitations like the need for complex calculations
and memorising [256]. As many as half of the positive cul-
tures represent contaminants – organisms (usually coagu-
lase negative staphylococci) inoculated from the skin at the
time of sample collection. False-positive blood cultures ex-
pose patients to potential harm like additional diagnostic
testing (additional blood cultures, echocardiograms, etc.),
unnecessary antibiotic administration, missed alternative
(infectious or non-infectious) diagnoses and prolonged
hospitalisation [169]. PCT also seems to differentiate con-
taminants from true positive blood cultures [173].
In summary, PCT is the most reliable of the currently
known circulating markers of systemic bacterial infections
(“sepsis”); it is the only one that correlates well with its
presence, course, and outcome in humans. PCT-guided an-
tibiotic de-escalation therapy is considered evidence-based
state-of-the-art in respiratory tract infections and recom-
mended by updated guidelines [62, 257]. The hypothesis
that hormokines are not only biomarkers but have a pivotal
role in the pathophysiology of sepsis is at the least attract-
ive, and at best intuitively obvious.
Epilogue
“With the rapid extension of laboratory tests of greater ac-
curacy, there is a tendency that for reaching a final diagnos-
is clinicians and students rely more and more on laboratory
reports and less on the patients history, the examination and
behaviour of the patient, and clinical judgment. While in
many cases laboratory findings are invaluable for reaching
correct conclusions, the student should never be allowed
to forget that it takes a man, not a machine, to understand
Figure 4
Personalised clinical and biomarker-guided medicine in the
emergency department.
POC = point of care; MTS = Manchester Triage Score; ProADM =
proadrenomedullin; ICM = intermediate care; CCU = coronary care
unit; ICU = intensive care unit; Lab = laboratory analysis of
biomarker level; X-ray = chest radiography; ACS = acute coronary
syndrome; AHF = acute heart failure; RTI = respiratory tract
infections; hs = highly sensitive; DD, = differential diagnosis
a man.” A seemingly contemporary statement from 1946!
[258].
Some decry the loss of clinical skills with history taking
and physical examination in routine patient care. Others
suggest that emphasis on clinical skills is from a bygone
era and that the availability of advanced imaging tech-
niques and laboratory tests have supplanted ambiguous his-
tory and physical findings [26]. As usual, both extremes
are irrational. The allegedly infallible impact of proper his-
tory and clinical exams in “the good old days” might ap-
pear nostalgic and outdated if applied to the more complex
and diversified differential diagnostic spectrum and thera-
peutic options of modern medicine. Conversely, over-reli-
ance on the new procedures contributes directly to misdia-
gnosis. Too often, palpably illogical laboratory findings are
accepted without question [259]. Technology is an adjunct
to clinical judgment and should not become a “gold stand-
ard” for diagnosis alone.
Proper risk stratification with biomarkers helps caregivers
to more appropriately direct diagnostic, monitoring, or
therapeutic interventions. Adverse events due to delays are
a major contributor for adverse hospital outcome. In a busy
emergency room, however, it is difficult or even impossible
to identify patients in whom harm would have been pre-
vented by more aggressive intervention. Substantial evid-
ence exists for many conditions – sepsis for example –
showing that earlier and more targeted intervention can im-
prove patient outcomes, especially with the use of proto-
cols or guidelines. Selected diagnostic and prognostic bio-
markers should and will have a more prominent role in
future emergency triage [260]. More personalised, better-
targeted healthcare resource application offers opportunit-
ies to improve timeliness, safety, efficacy, and cost-effect-
iveness of care, as well as quality-of-life of patients and
their loved ones. Rationalising for prevention of rationing
is the credo!
The future of biomarkers lies in intervention studies across
heterogeneous populations in combination with clinical
scores and close to “real-life” settings. Comprehensive ef-
fectiveness research studies are being carried out aiming
to further validate these concepts in “real-world-settings”
and thereby improve patient care [261]. Results of these
trials may ultimately help to transition from bundled treat-
ment strategies to more individualised patient care thereby
providing better, hopefully still empathic, management for
the allocation of limited patient and societal resources (fig.
4).
Finally, as physicians we should always be aware that, be-
fore and after all, a patients is a human being seeking
help. After we have tried to explain to him all the medical
progress, fancy biomarkers for personalized diagnosis and
novel options for individualised therapy, we might be
puzzled by the question of the patient “Personalised medi-
cine, doctor, does this mean that you have more personal
time for taking care of me?”
Key issues
‒ Every medical therapy in emergency care has potential
adverse effects and expedited selection of patients most
likely to benefit is crucial, making more personalised
approaches necessary.
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‒ Specific blood biomarkers may allow transition from
generalising care bundles to a more tailored manage-
ment in individual patients thereby reducing the risk for
adverse treatment outcomes in patients who – based on
their biomarker levels – do not likely benefit from ther-
apy.
‒ Biomarkers measured on admission and during follow-
up can support the clinician’s early recognition of car-
diorespiratory, inflammatory and infectious diseases,
severity assessment with adequate site-of care de-
cisions and most effective therapeutic decisions in indi-
vidual patients.
‒ Proadrenomedullin (ProADM) is an inflammatory pro-
gnostic marker that improves early mortality prediction
and might improve site-of-care decisions, as tested in
patients with respiratory infections.
‒ Initial D-dimer testing should be done when evaluating
patients with either a low (with either a moderately or
highly sensitive D-dimer test) or moderate clinical
probability (highly sensitive D-dimer only) of venous
thromboembolism (VTE). If the D-dimer test is negat-
ive (e.g. cut-off <500 μg/l) VTE is excluded, without
the need for further imaging.
‒ Cardiac troponin I and T are quantitative markers of
cardiomyocyte injury and indispensable tools in the
early diagnosis of AMI.
‒ Natriuretic peptides are quantitative markers of hemo-
dynamic cardiac stress and indispensable tools in the
early diagnosis of acute heart failure
‒ C-reactive protein (CRP), as marker for more subtle
sub-acute inflammation has a role in the risk selection
for statin therapy in primary prevention of cardiovascu-
lar diseases.
‒ Procalcitonin (PCT) algorithms facilitate assessment of
bacterial infection risk and appear to be safe in guiding
therapeutic decisions about initiation and duration of
anti-microbial therapy in infections with respiratory
origin regarding the results from interventional trials.
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Figures (large format)
Figure 1
Combined clinical and biomarker assessment for a personalised emergency triage, therapeutic intervention and site of care decisions.
Figure 2
Systemic multiprofessional risk assessment for improve patient management adapted from [261].
ProADM = proadrenomedullin
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Figure 3
CURB-A score combining the traditional CURB-65 criteria with levels of proADM to risk stratify site-of-care decisions in patients with lower
respiratory tract infections.
ICU = intensive care unit; ProADM = pro-adrenomedullin; SP = Selbstpflege (self-care); PACD = post-acute care discharge
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Figure 4
Personalised clinical and biomarker-guided medicine in the emergency department.
POC = point of care; MTS = Manchester Triage Score; ProADM = proadrenomedullin; ICM = intermediate care; CCU = coronary care unit; ICU
= intensive care unit; Lab = laboratory analysis of biomarker level; X-ray = chest radiography; ACS = acute coronary syndrome; AHF = acute
heart failure; RTI = respiratory tract infections; hs = highly sensitive; DD, = differential diagnosis
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